Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004

NCT03795428 is registered in ClinicalTrials.gov with PhaseBio Pharmaceuticals Inc. as lead sponsor.

NCT NCT03795428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03795428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Terminated
Start date
April 10, 2019
Completion date
January 11, 2022
Enrollment
25 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension